Israeli clinical-stage immunotherapy company Enlivex Therapeutics announced the purchase of Bitcoin as the company's asset reserve

Wu Shuo learned that Enlivex Therapeutics, an Israeli clinical-stage immunotherapy company, announced that its board of directors approved the purchase of up to $1 million in BTC as part of its cash management strategy. The company is listed on the Nasdaq in the United States (code: ENLV), and CEO Oren Hershkovitz stated that with the rise in BTC demand and acceptance, coupled with the approval of BTC ETFs and support from institutional investors, the company believes that BTC can serve as a strong asset reserve, providing value storage and anti-inflation functions.

View Original
  • Reward
  • Comment
  • Share
Comment
No comments